Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

VBI Vaccines Inc. VBIV NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

VBI Vaccines Inc. (VBIV) is a Biotechnology company in the Healthcare sector, currently trading at $0.07. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $9M, +244.4%/yr average growth. Net income is $93M (loss), growing at -37.8%/yr. Net profit margin is -1069.3% (negative). Gross margin is -67% (+697.1 pp trend).

Balance sheet: total debt is $53M against $8M equity (Debt-to-Equity (D/E) ratio 7.05, leveraged). Current ratio is 0.48 (tight liquidity). Debt-to-assets is 61%. Total assets: $87M.

Analyst outlook: 6 / 6 analysts rate VBIV as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 0/100 (Fail), Moat 15/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

VBIV SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VBIV

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
VBIV: +244.4%/yr revenue is, -37.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
✗
MOAT Fail
15/100
VBIV: Gross margin is -67% (+697.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 6 / 6 analysts rate VBIV as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VBIV: Net profit margin is -1069.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0574-1.35
Volume27.93M
Avg Volume (30D)8.39M
Market Cap$1.87M
Beta (1Y)2.17
Share Statistics
EPS (TTM)-5.96
Shares Outstanding$15.57M
IPO Date2010-04-26
Employees131
CEOJeffery R. Baxter FCMA
Financial Highlights & Ratios
Revenue (TTM)$8.68M
Gross Profit$-5.82M
EBITDA$-53.32M
Net Income$-92.84M
Operating Income$-55.31M
Total Cash$23.69M
Total Debt$53.04M
Net Debt$29.36M
Total Assets$86.95M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.22
Analyst Forecast
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA91822J2020

Price Chart

Track all markets on TradingView
VBIV
VBI Vaccines Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.06 52WK RANGE 1.35

People Also View

BBIO
BBIO
BridgeBio Pharma, Inc.
$77.70
-0.30%
 IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 AUPH
AUPH
Aurinia Pharmaceuticals Inc.
$16.05
-0.12%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 OCGN
OCGN
Ocugen, Inc.
$1.95
+8.33%
 ALLO
ALLO
Allogene Therapeutics, Inc.
$2.17
-4.82%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$14.34
+7.42%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message